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Abstract 
 
Background: Global dietary recommendations for and cardiovascular effects of linoleic acid, 
the major dietary omega-6 fatty acid, and its major metabolite, arachidonic acid, remain 
controversial. To address this uncertainty and inform international recommendations, we 
evaluated how in vivo circulating and tissue levels of linoleic acid (LA) and arachidonic acid 
(AA) relate to incident cardiovascular disease (CVD) across multiple international studies. 
Methods: We performed harmonized, de novo, individual-level analyses in a global consortium 
of 30 prospective observational studies from 13 countries. Multivariable-adjusted associations of 
circulating and adipose tissue LA and AA biomarkers with incident total CVD and subtypes 
(coronary heart disease (CHD), ischemic stroke, cardiovascular mortality) were investigated 
according to a prespecified analytical plan. Levels of LA and AA, measured as % of total fatty 
acids, were evaluated linearly according to their interquintile range (i.e., the range between the 
mid-point of the first and fifth quintiles), and categorically by quintiles. Study-specific results 
were pooled using inverse-variance weighted meta-analysis. Heterogeneity was explored by age, 
sex, race, diabetes, statin use, aspirin use, omega-3 levels, and fatty acid desaturase 1 genotype 
(when available).  
Results: In 30 prospective studies with medians of follow-up ranging 2.5 to 31.9 years, 15,198 
incident cardiovascular events occurred among 68,659 participants. Higher levels of LA were 
significantly associated with lower risks of total CVD, cardiovascular mortality, and ischemic 
stroke, with hazard ratios per interquintile range of 0.93 (95% CI: 0.88-0.99), 0.78 (0.70-0.85), 
and 0.88 (0.79-0.98), respectively, and nonsignificantly with lower CHD risk (0.94; 0.88-1.00). 
Relationships were similar for LA evaluated across quintiles. AA levels were not associated with 
higher risk of cardiovascular outcomes; comparing extreme quintiles, higher levels were 
associated with lower risk of total CVD (0.92; 0.86-0.99). No consistent heterogeneity by 
population subgroups was identified in the observed relationships.  
Conclusions: In pooled global analyses, higher in vivo circulating and tissue levels of LA and 
possibly AA were associated with lower risk of major cardiovascular events. These results 
support a favorable role for LA in CVD prevention.  
 
Key Words: Linoleic acid; Arachidonic acid; Pooled analysis; Cardiovascular Disease; Diet and 
Nutrition; Epidemiology; Primary Prevention; Biomarkers   
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Clinical Perspective 
 
What is new?  
• We conducted the hitherto largest pooled individual-level analysis using circulating 
and adipose tissue levels of linoleic acid and arachidonic acid to examine the link 
between omega-6 fatty acids and cardiovascular outcomes in various populations. 
• Our approach increases statistical power and generalizability compared to individual 
studies; lowers the risk of publication bias and heterogeneity compared to meta-
analyses of existing literature; and allows evaluation of the associations in key 
population subgroups.  
• Strikingly, higher level of linoleic acid was associated with lower risks of total 
cardiovascular disease, ischemic stroke, and cardiovascular mortality, while 
arachidonic acid was not associated with cardiovascular risk. 
 
What are the clinical implications? 
• Our findings support potential benefits of the main dietary omega-6 fatty acid, i.e., 
linoleic acid, for cardiovascular disease prevention. 
• Furthermore, our results do not support any theorized cardiovascular harms of omega-
6 fatty acids. 
• Our findings provide evidence to help inform currently inconsistent global dietary 
recommendations on omega-6 consumption. 
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Introduction  
Recommendations for dietary consumption omega-6 (n-6) polyunsaturated fatty acids (PUFA) 
for cardiovascular disease (CVD) prevention remain controversial and inconsistent.1 For 
example, the American Heart Association and the Academy of Nutrition and Dietetics 
recommend 5-10%,1, 2 the United Nations Food and Agriculture Organization recommends 2.5-
9%,3 while the French national guidelines recommend 4%.4 Pooled evidence from clinical trials 
and cohort studies suggests a moderate benefit of consuming n-6 PUFA, predominantly linoleic 
acid (LA, 18:2n-6), for coronary heart disease (CHD) risk, whether replacing saturated fat or 
total carbohydrate.5-7 In contrast, recent secondary analyses of clinical trials of LA-rich corn oil 
(although not LA-rich soybean oil) conducted in the 1960s-1970s suggest a possible increased 
risk of overall and CHD mortality.8, 9 The interpretation of these latter trials is hampered by their 
short duration,8, 9 small numbers of events,8 substantial drop-out,9 and confounding by industrial 
trans-fats.8, 9 In addition, many of the other prior trials are limited by lack of blinding or 
randomization, and major dietary pattern shifts; and most are decades old, creating potentially 
low generalizability to contemporary diets and clinical settings. Cohort studies are limited by the 
common reliance on self-reported dietary habits, which can be influenced by memory errors and 
inaccurate nutrient databases. Thus, for many scientists, clinicians, and policy makers, the role of 
LA in CVD risk remains uncertain. 
 In addition, concerns have been raised that n-6 PUFA could actually increase CVD risk, 
due to potential pro-inflammatory effects.9, 10 LA is a precursor of the n-6 PUFA arachidonic 
acid (AA, 20:4n-6), which gives rise to a range of eicosanoids considered to be pro-inflammatory 
and pro-thrombotic.10, 11Yet, stable isotope studies suggest very limited conversion of LA to AA 
in humans,12 and trials show limited effects of increasing dietary LA on plasma and adipose 
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tissue AA levels.12-14 These findings indicate the importance of directly evaluating AA levels 
instead of inferring them from LA levels or intakes in relation to CVD risk. As LA cannot be 
produced endogenously (making tissue levels reasonable markers of intake), biomarker 
(circulating and adipose tissue) levels correlate with dietary consumption.15, 16 Such objective 
biomarkers allow evaluation of dietary exposure of LA status independent of self-reported food 
habits and estimated nutrient composition of different foods. Circulating and adipose biomarkers 
also allow direct evaluation of AA, which is highly metabolically regulated and for which dietary 
estimates correlate poorly with in vivo levels.  
 Yet, the relations between in vivo levels of LA and AA and CHD risk have been 
evaluated in relatively few studies, with different study designs, outcomes, exposures (e.g., lipid 
compartment), covariates, and statistical methodology. Results from meta-analyses of published 
studies using circulating or adipose tissue levels of n-6 PUFA have been contradictory.17, 18 
Furthermore, associations between in vivo n-6 PUFA levels and other CVD outcomes including 
stroke, total CVD, and CVD mortality have been studied less frequently19-23 and remain 
uncertain. 
 To address these major gaps in knowledge, we conducted a pooled analysis of 
harmonized, de novo, individual-level data across 30 cohort studies in the Fatty Acid and 
Outcome Research Consortium (FORCE) to evaluate associations of LA and AA levels with 
incident total CVD and subtypes (CHD, ischemic stroke, CVD mortality). 
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Methods 
Data Availability 
The institutional review board approvals and data sharing agreements for the participating 
cohorts allowed us to share cohort results. Individual participant data are owned by individual 
participating cohorts and are available to researchers consented from participating cohorts. For 
further queries or requests, please contact force@tufts.edu. Further details are available at the 
FORCE website: http://force.nutrition.tufts.edu/. 
Study setting and population: FORCE Consortium  
The study was conducted within FORCE (http://force.nutrition.tufts.edu), a consortium of studies 
with circulating or adipose tissue fatty acid biomarker measurements and ascertained chronic 
disease events.24 Studies were identified and invited to participate if assessing biomarker 
(circulating or adipose tissue) levels of LA and AA, and incident CVD (or subtypes thereof), 
based on previous FORCE projects,24, 25 expert contacts, and online searches. Studies with adult 
participants (≥18 y) free of CVD (myocardial infarction, angina, coronary revascularization, 
stroke) at the time of fatty acid sampling were invited. Retrospective case-control studies were 
included in a sensitivity analysis if fatty acids were assessed in adipose tissue, which have a long 
half-life of exposure.26 To minimize potential reverse causation, the main analysis included only 
prospective studies. Of 38 studies invited by September 2017, 31 participated (Table 1 and 
Supplemental Tables 1-2 in the online-only Data Supplement), while 7 were ineligible, declined 
to participate, or failed to respond (Supplemental Table 3 in the online-only Data Supplement). 
The study was approved by the institutional review boards of the participating cohorts. 
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Fatty acid measurements 
Studies measured fatty acids in differing compartments, including plasma phospholipids, 
erythrocytes, plasma, serum, cholesterol esters, and adipose tissue. All fatty acid levels were 
reported as percent of total fatty acids. Detailed information regarding fatty acid measurements 
in each study is provided in the Supplemental Material.  
Outcome assessment 
In each cohort, study participants were excluded if they were children (age <18 years) or had 
prevalent CVD at the time of fatty acid measurement. Among the remaining participants, we 
evaluated incident CVD (defined as incident CHD or stroke) and its subtypes including CHD 
(fatal or nonfatal myocardial infarction, CHD death, or sudden cardiac death), ischemic stroke 
(fatal or nonfatal ischemic stroke), and CVD mortality (the subset of fatal events from these 
causes). Studies that did not separately assess ischemic stroke used total stroke (n=5 studies). 
Detailed information on outcomes in each study is provided in the Supplemental Material. 
Covariates 
To minimize potential confounding, prespecified and harmonized covariates were utilized 
included age (years), sex (male/female), race (Caucasian/non-Caucasian, or study-specific), field 
center if applicable (categories), body-mass index (BMI, kg/m2), education (less than high school 
graduate, high school graduate, some college or vocational school, college graduate), smoking 
(current, former, never; if history not assessed, then current/not current), physical activity 
(quintiles of metabolic equivalents (METs)/ week), alcohol intake (none, 1-6 drinks/week, 1-2 
drinks/day, >2 drinks/day), prevalent diabetes mellitus (defined as treatment with oral 
antihyperglycemic agents, insulin, or fasting plasma glucose >126 mg/dL), treated hypertension 
(defined as hypertension drug use; or if unavailable, as diagnosed/history of hypertension), 
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treated hypercholesterolemia (defined as LDL-lowering drug use; if unavailable, as 
diagnosed/history of hypercholesterolemia), regular aspirin use (defined as ≥2 times/week), 
levels of α-linolenic acid (ALA; 18:3n-3), eicosapentaenoic acid (EPA; 20:5n-3), sum of trans 
isomers of oleic acid (trans18:1), and sum of trans isomers of LA (trans-18:2) (each expressed 
as % total FAs). If data did not allow such categorization, study-specific categories were used. 
Imputation was allowed for linear covariates if previously established in each cohort; missing 
indicator categories were utilized for missing covariate data in categories.  
Statistical analysis and pooling 
All participating studies followed a prespecified, harmonized analysis protocol with standardized 
exclusions, exposures, outcomes, covariates, and analytical methods. In each study, de novo 
analyses of individual data were performed according to the protocol. Cox and weighted Cox 
proportional hazards models were used to estimate hazard ratios in cohort and nested unmatched 
case-cohort studies, respectively, with follow-up from the date of blood or adipose tissue 
sampling to date of incident event, death, loss to follow-up, or end of follow-up. In matched 
nested case-control studies, conditional logistic regression was used to estimate odds-ratios for 
each outcome, considered to approximate hazard ratios. To assess potential nonlinear 
associations, each cohort also evaluated study-specific quintiles as indicator categories, with the 
lowest quintile as the reference. Studies assessing fatty acids in multiple compartments 
conducted separate analyses in each compartment. To investigate potential heterogeneity by 
other factors, associations in each study were also assessed in prespecified strata by age, sex, 
race, ALA and EPA levels, prevalent diabetes, drug-treated hypercholesterolemia, and regular 
aspirin use. Potential interactions by genotype were examined in the 14 studies with available 
data for rs174547 (single nucleotide polymorphism in the gene for fatty acid desaturase 1, a 
D
ow
nloaded from
 http://ahajournals.org by on April 12, 2019
10.1161/CIRCULATIONAHA.118.038908 
9 
major genetic determinant of circulating LA and AA).27 Interaction terms were constructed as a 
cross-product of LA or AA and rs174547 (as an additive effect: 0, 1, or 2 T-alleles) and included 
with the main effects in the models. Robust variance was used in all analyses.  
 Results from each study were provided to the lead author in standardized electronic forms 
and pooled using inverse-variance weighted meta-analysis. The results were pooled overall and 
within each specific type of fatty acid compartment including phospholipids (erythrocyte 
phospholipids or plasma phospholipids), total plasma, cholesterol esters, and adipose tissue. To 
allow comparison and pooling of results across different compartments, LA and AA 
concentrations were standardized to study-specific interquintile range defined as the range 
between the midpoint of the first and fifth quintiles (i.e., range between 10th and 90th 
percentiles).Potential semi-parametric associations were assessed by meta-regression with 
restricted cubic splines constructed from study-specific quintiles.28  
 Overall heterogeneity was assessed by the I2-statistic, with values of ~ 25%, 50%, and 
75%, considered to indicate low, medium, and high heterogeneity, respectively.29 Heterogeneity 
between prespecified subgroups was explored by meta-analyzing study-specific effect estimates 
from each stratum, with statistical differences between subgroups tested by meta-regression. 
Potential interactions by desaturase genotype were examined by meta-analyzing study-specific 
interaction terms. For each study, associations of n-6 PUFA with CVD per genotype at rs174547 
(i.e, CC, CT, or TT) were calculated from beta coefficients and the variance-covariance matrix of 
the main and interaction terms.24 The genotype-specific estimates were pooled using pooled 
using inverse-variance weighted meta-analysis. While subgroups were prespecified, all 
heterogeneity analyses were considered exploratory and Bonferroni-corrected for multiple 
comparisons (10 subgroups; corrected α=0.005).  
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 In sensitivity analyses, we evaluated compartment-specific associations using absolute 
percent of total fatty acids as the unit of exposure, instead of study-specific interquintile range. In 
other sensitivity analyses, we censored events at maximum 10 y of follow-up, to minimize bias 
by changes in fatty acid levels over time; used alternative blood compartments in the overall 
pooled analysis for studies having more than one measure; included one retrospective study; and 
excluded studies assessing only fatal outcomes. 
Meta-analyses were performed using Stata 13 (StataCorp, College Station, TX), with two-tailed 
α=0.05 for the primary analyses. 
 
Results  
The pooled analyses included 76,356 fatty acid measurements from 68,659 participants in 30 
prospective studies from 13 countries (Table 1). The studies included 18 cohort and 12 nested 
case-control or case-cohort studies. Most studies assessed fatty acids in blood compartments 
(plasma phospholipids, n=11 studies; erythrocyte phospholipids, total plasma, or cholesterol 
esters, n=7 studies each), while adipose tissue was less commonly used (n=3 studies).  One 
retrospective case-control study measuring adipose tissue biomarkers was included in a 
sensitivity analysis, but not in the primary analyses.  
 Across studies, mean age at baseline ranged from 49 to 77 years (Table 1 and 
Supplemental Table 4). Overall proportions of women and men were comparable, although some 
studies included one sex only (Table 1). Most participants were Caucasian, but several studies 
included sizable numbers of African Americans, Asians, and Hispanics (Supplemental Table 5). 
In most studies, up to 30% of the participants smoked, and alcohol intake was generally 
moderate (<1 drink/d). Education level, diabetes prevalence, and medication use varied across 
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studies. As would be expected, levels of fatty acids varied between different compartments 
(Figure 1 and Supplemental Tables 4 and 6). 
 Median study follow-up durations ranged from 2.5 to 31.9 years. Among the 30 
prospective studies, 10,477 total incident CVD events, 4,508 CVD deaths, 11,857 incident CHD 
events, and 3,705 incident ischemic strokes occurred (Supplemental Table 7).  
 Per interquintile range, higher LA levels were associated with 7% (95%CI: 1-12%), 22% 
(15-30%), and 12% (2-21%) lower incidence of total CVD, CVD mortality, and ischemic stroke, 
respectively (Figures 2-3, Table 2). LA levels were also nonsignificantly (P=0.065) associated 
with lower incidence of total CHD. Overall heterogeneity was moderate (I2=28-63%). 
Associations of LA with total CVD, total CHD, and CVD mortality varied by compartment (P-
interaction≤0.031), with generally less prominent inverse associations in studies utilizing 
phospholipids (Figures 2-3).  
 Compared to the lowest quintile, participants in the highest quintile of LA levels 
experienced lower risk of CVD mortality (HR=0.77; 95% CI, 0.69-0.86), with nonsignificant 
trends toward lower risk of total CVD (0.94; 0.87-1.01), CHD (0.92; 0.85-1.00), and ischemic 
stroke (0.90; 0.79-1.02) (Supplemental Table 8). There was no significant evidence of non-linear 
associations between LA and each outcome (P-nonlinearity>0.05 each). 
 AA levels evaluated linearly were not significantly associated with CVD events, with a 
hazard ratio of 0.95 (0.90-1.01) for total CVD (Table 2, Figures 4-5). When different lipid 
compartments were assessed, AA levels in total plasma, but not other compartments, were 
associated with lower risk of total CVD (HR=0.81 (0.70-0.94) (Table 2, Figure 4). Overall 
heterogeneity was low to moderate (I2≤54%). When AA levels were evaluated in quintiles 
(Supplemental Table 9), participants in the highest quintile, compared to the lowest, experienced 
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significantly lower incidence of total CVD (0.92; 0.86-0.99). There was evidence for a 
borderline nonlinear association (P-nonlinearity=0.039) between total plasma AA and ischemic 
stroke (Supplemental Figure 1).  
 Associations of LA and AA with CVD outcomes did not significantly differ according to 
subgroups defined by age, sex, race, n-3 PUFA levels, diabetes status, statin use, aspirin use, or 
baseline year of fatty acid measurement (Supplemental Table 10). In 14 studies with genotype 
data (Supplemental Table 11), a significant interaction (P-interaction=0.002) was observed 
between LA and rs174547 genotype in relation to risk of ischemic stroke (Supplemental Table 
12), with inverse associations appearing stronger in carriers of the major T-allele. The 
associations of AA with cardiovascular outcomes did not significantly vary by rs174547 
genotype. 
 In sensitivity analyses, results of compartment-specific analysis that utilized units of 
percent of total fatty acids, rather than study-specific interquintile ranges, were not appreciably 
different from the main findings (Supplemental Table 13). Results were also similar across all 
other sensitivity analyses (Supplemental Table 14).  
 
Discussion 
In this harmonized, individual-level pooled analysis across 30 prospective studies from 13 
countries, higher in vivo levels of the n-6 PUFA LA were associated with lower risk of CVD 
events, in particular CVD mortality and stroke. AA levels were not associated with higher risk, 
and were associated with lower CVD risk in some analyses. To our knowledge, this is the largest 
pooled analysis of fatty acid levels and CVD endpoints, including almost 70,000 individuals and 
10,000 total CVD events.  
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 Our findings provide evidence to help inform currently inconsistent global dietary 
recommendations on n-6 PUFA consumption. LA, an essential fatty acid not synthesized by 
humans, is the main dietary PUFA, comprising about 85-90% of the total. While circulating and 
adipose tissue LA levels can be influenced by metabolism,27, 30 they are established and useful 
markers of diet as they increase in a dose-response manner in response to dietary LA in 
controlled feeding trials15, 26, 30 and consistently correlate with self-reported dietary estimates in 
large cohort studies,26 including a considerable number of studies participating in the current 
analysis (Supplemental Table 15). Several lines of evidence support mechanisms by which 
dietary LA may reduce CVD. In randomized controlled feeding trials, dietary PUFA (primarily 
LA) as a replacement for either carbohydrates or saturated fat lowers low density lipoprotein 
(LDL)-cholesterol, triglycerides, and ApoB levels, and raises high density lipoprotein (HDL)-
cholesterol;14, 31 and also lowers hemoglobin A1c and insulin resistance and potentially augments 
insulin production.32 Other potential cardiometabolic benefits of dietary LA may include 
favorable effects on inflammation,14 blood pressure,33 and body composition, including 
prevention and reduction of visceral and liver fat.14, 34 In a pooled analyses of prospective cohort 
studies, self-reported estimates of LA consumption are associated with lower CHD risk.6 
Similarly, in meta-analyses of older, limited clinical trials, increased consumption of LA-rich 
vegetable oils, especially soybean oil, reduces the risk of CHD.5 Our findings evaluating in vivo 
levels of LA status across multiple global studies add strong support for cardiovascular benefits 
of LA.  
 While AA has long been considered an archetypical pro-inflammatory and pro-
thrombotic fatty acid, growing evidence suggests its effects may be more complex.35 In the 
present investigation, AA levels were not associated with higher risk of CVD, and indeed in 
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some analyses were associated with lower risk. These results do not provide support for adverse 
cardiovascular effects of AA. While AA is the precursor to potentially pro-inflammatory 
leukotrienes, it is also the main precursor to key anti-inflammatory metabolites, such as 
epoxyeicosatrienoic acids and prostaglandin E2, as well as other mediators that actively resolve 
inflammation, such as lipoxin A4. 35 It also gives rise to prostacyclin, a potent anti-aggregatory 
and vasodilatory molecule.36 These complex biologic effects preclude simplistic inference on 
health effects of AA metabolites and further support the importance of empiric assessment of 
relationships with clinical events, such as in our investigation. 
 Overall, our findings provide little support for the hypothesis that LA or AA, the major n-
6 PUFA, may increase CVD risk. We also identified little evidence for any interaction between 
n-6 and n-3 PUFA levels, consistent with prior reviews of dietary data.1 n-6 PUFA may also 
have additional metabolic benefits. For example, a recent pooled analysis from FORCE 
identified a strong inverse association of circulating and adipose tissue LA levels and incidence 
of type 2 diabetes, with no significant associations for AA.25 Taken together with results of 
randomized controlled feeding trials of blood lipids, glucose-insulin homeostasis, and other 
metabolic risk factors; prospective cohort studies of self-reported consumption; and (older, 
methodologically limited) clinical trials of LA-rich plant oils, our novel findings do not support 
recommendations of some10 to reduce n-6 PUFA consumption or reduce the n-6:n-3 ratio (as 
opposed to increasing n-3 intake). Rather, the findings from the present study, together with the 
prior research summarized above, support independent cardioprotective benefits of LA.  
 Our results provide important evidence that helps inform clinical and population 
recommendations. Dietary guidelines from several organizations, including the American Heart 
Association, recommend increased consumption of n-6 PUFA to prevent CVD.7 However, some 
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researchers9, 10, 37 and other national guidelines4 currently recommend avoidance of n-6 PUFA 
and reductions from current intake levels. Furthermore, current trends in oil production are 
leading to increased use of high-oleic, LA-depleted seed oils,38 which can increase the risk of 
insufficient PUFA consumption in population subgroups. Our findings, combined with prior 
evidence from metabolic feeding trials, supports cardiovascular benefits of LA and a need to 
harmonize international guidelines and priorities for oilseed production and use. 
 A unique strength of our investigation was the ability to assess associations across 
distinct lipid compartments across which LA (AA) levels intercorrelate to varying degrees (e.g., 
r=0.4-0.9),26, 39, 40 suggesting that each compartment reflects partly differing metabolic and 
physiologic influences. Yet, our findings were generally concordant across compartments, 
providing support for common or similar biologic effects of these n-6 fatty acids across these 
compartments.  
 The inverse association of LA levels with ischemic stroke was more pronounced in T-
allele carriers of rs174547, a polymorphism in FADS1 associated with higher fatty acid 
desaturase activities27, 41 and FADS1 expression.42 Although located in FADS1, rs174547 is also 
in strong linkage disequilibrium with polymorphisms in FADS2 (encoding the LA-desaturating 
FADS2) and has emerged as the main genetic determinant of circulating LA and AA in a recent 
genome-wide association study.27 The T-allele has been linked to several metabolic traits 
including higher cholesterol (total, LDL, and HDL)43 and fasting glucose44, but also lower 
triglycerides43 and heart rate.45 The pleiotropy of the FADS cluster and the specificity for 
ischemic stroke rather than all CVD endpoints complicates the interpretation of the observed 
gene-LA interaction, which should therefore be viewed cautiously. Yet, one could also speculate 
that carriers of the major T-allele derive greater benefits from the established LDL-lowering 
D
ow
nloaded from
 http://ahajournals.org by on April 12, 2019
10.1161/CIRCULATIONAHA.118.038908 
16 
effects of dietary LA and thus have accentuated health benefits –a ripe area for further 
investigation.  
 Few prior meta-analyses of LA and AA levels in CVD have been performed. In one 
analysis of 10 published studies with 28,000 participants and 3,800 events, LA was not 
significantly associated with coronary events, while AA was associated with a 17% reduction in 
risk.18 In a meta-analysis of published studies acute myocardial infarction and coronary 
syndromes including many retrospective case-control studies, circulating and adipose tissue LA 
levels were inversely associated with the risk of CHD events, while overall associations for AA 
were null.17 Our investigation considerably extends these prior results by focusing on prospective 
studies, performing new individual-level study-specific analyses using a standardized and 
harmonized analysis protocol, including a much larger number of participants and events, and 
evaluating several major CVD outcomes. Importantly, our consortium also greatly minimizes 
publication bias by incorporating new (unpublished) findings from all available studies, rather 
than pooling only prior published results. 
 Other strengths include use of in vivo n-6 PUFA levels, which complement self-reported 
dietary estimates, reduce errors from memory, and allow assessment of biologically relevant in 
vivo levels- especially important for AA. Outcomes in nearly all studies were defined by 
centralized adjudication processes or validated registries rather than from self-report alone, 
reducing the potential for missed or misclassified endpoints. Inclusion of cohorts from 13 
countries across several continents enhances generalizability. The large numbers of participants 
and events allowed us to explore several potential effect modifiers and the shape of the 
associations.  
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 Potential limitations deserve attention. For certain compartments, such as adipose tissue, 
few studies were available. Most individuals were of European descent, lowering statistical 
power for evaluating other races/ethnicities. Despite extensive efforts to harmonize study-
specific methods, some dissimilarities remained between cohorts in outcome definitions (see 
Expanded Methods in the Supplemental Material) and covariate categorization (Supplemental 
Table 5). Although such variety and unmeasured background population characteristics may 
increase generalizability, these may also have contributed to the moderate between-study 
heterogeneity observed for some exposure-outcome relationships. Fatty acids were measured 
once at baseline, and changes over time could lead to misclassification, which would attenuate 
the associations. However, reasonable temporal reproducibility has been reported for LA and AA 
concentrations over time.46 Since few studies evaluated multiple compartments, and because 
cholesterol esters were only assessed by studies from Northern Europe, we were hampered in 
drawing any conclusions of true predictive differences between lipid fractions. Although fatty 
acid analytical methods were not standardized across studies, the use of a quintile-based 
statistical approach minimizes this concern. We did not adjust for non-fatty acid dietary factors, 
but pooling results across multiple cohorts with different population characteristics increases the 
validity of the findings. While all studies consistently adjusted for other major CVD risk factors, 
we cannot exclude residual confounding due to unmeasured or imprecisely measured covariates. 
However, the concordance of the present observed associations with other lines of evidence on 
cardiovascular benefits of LA1, 5, 6, 32 provide biologic plausibility for our findings. We did not 
evaluate the associations after exclusion of early cases. However, such sensitivity did not 
produce results substantially different from the main findings in our previous pooling 
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projects24,25 and in cohort-specific analyses,23 suggesting that the observed associations are not 
likely due to reverse causation.  
 In summary, based on pooled individual-level analyses of prospective studies, circulating 
and adipose tissue biomarker concentrations of LA were inversely associated with CVD while 
AA was not associated with higher CVD risk. Together with prior research, these results support 
CVD benefits of LA.  
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Table 1. Characteristics of 31 studies and baseline characteristics of individual study participants with linoleic acid (LA; 18:2n6) and 
arachidonic acid (AA; 20:4n6) biomarker measures and follow-up for cardiovascular disease incidence or mortality.* 
 
Study† Country 
Study 
design‡ 
Age, y 
(mean) 
Sex  
(% male) 
BMI, kg/m2 
(mean) 
Biomarker 
compartment§ 
Year of 
biomarker 
sampling Outcome assessed|| 
AGES-Reykjavik Iceland PC 77 39 27.1 PP 2002-2006 All# 
ARIC USA PC 54 52 27.0 PP 1987-1989 All 
CCCC Taiwan PC 61 55 23.3 TP 1992-2000 All 
CHS USA PC 73 36 26.7 PP 1992-1993 All 
CRS Costa Rica RCC 58 73 26.2 AT 1994-2004 Non-fatal MI 
DCH Denmark PNC 57 61 26.6 AT** 1993-1997 Total CHD 
EPIC-Norfolk UK PCC 63 49 26.5 PP 1993-1997 All 
EPIC-Potsdam Germany PC 50 37 26.0 RBC 1994-1998 Total CVD 
FHS USA PC 66 43 28.2 RBC 2005-2008 All 
HPFS USA PCC 65 100 25.8 RBC, TP 1993-1995 Total CVD, CHD, & stroke 
HS Japan PC 61 42 23.1 TP 2002-2003 All 
KIHD Finland PC 52 100 26.7 TP 1984-1989 All 
MCCS Australia PC 56 46 27.2 PP 1990-1994 Fatal CVD, CHD, & 
ischemic stroke 
MESA USA PC 62 47 28.3 PP 2000-2002 All 
METSIM Finland PC 55 100 26.5 CE, PP, RBC 2006-2010 Total CVD 
MORGEN (CHD) Netherlands PCC 52 79 26.2 CE 1993-1997 Fatal CHD 
MORGEN (Stroke) Netherlands PCC 50 53 25.9 CE 1993-1997 Ischemic stroke 
MPCDRF Netherlands PCC 51 70 25.9 CE 1987-1991 Fatal CHD 
NHS USA PCC 60 0 25.6 RBC, TP 1989-1990 Total CVD, CHD & stroke 
NSHDS I Sweden PCC 54 79 26.2 PP 1987-1994 Total CHD 
NSHDS II Sweden PCC 54 76 26.4 PP 1987-1999 Total CHD 
NSHDS III Sweden PCC 55 61 26.7 PP 1987-1995 Ischemic stroke 
PHS USA PCC 69 100 25.7 RBC 1995-2001 Total CHD 
PIVUS Sweden PC 70 47 26.9 CE, PP 2001-2004 All 
SCHS Singapore PCC 66 65 23.0 TP 1994-2005 Total CHD 
SHHEC UK PC 49 52 25.6 AT 1985-1986 All 
60YO Sweden PC 60 48 26.8 CE 1997-1998 All 
3C Study France PC 75 39 26.0 TP 1999-2000 All 
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ULSAM-50†† Sweden PC 50 100 25.0 CE 1970-1973 All 
ULSAM-70†† Sweden PC 71 100 26.4 AT 1991-1995 All 
WHIMS USA PC 70 0 28.2 RBC 1996 All 
*AA, arachidonic acid; BMI, body mass index; LA, linoleic acid. †AGES-Reykjavik: Age, gene/environment susceptibility – Reykjavik Study; ARIC: 
Atherosclerosis Risk in Communities; CCCC: Chin-Shan Community Cardiovascular Cohort Study; CHS: Cardiovascular Health Study; CRS: Costa 
Rica study on adults; DCH: Diet, Cancer, and Health study; EPIC: European Prospective Investigation into Cancer; FHS: Framingham Heart Study; 
HPFS: Health Professionals Follow-up Study; HS: The Hisayama Study; KIHD: Kuopio Ischaemic Heart Disease Risk Factor Study; MCCS: 
Melbourne Collaborative Cohort Study; MESA: Multi-Ethnic Study of Atherosclerosis; METSIM: Metabolic syndrome in men study; MORGEN: 
Monitoring Project on Risk Factors for Chronic Diseases; MPCDRF: Monitoring Project on Cardiovascular Disease Risk Factors; NHS I: Nurses’ 
Health Study I; NSHDS I-III: Northern Sweden Health and Disease Study; PHS: Physicians’ Health Study; PIVUS: Prospective Investigation of the 
Vasculature in Uppsala Seniors; SCHS, Singapore Chinese Health Study; SHHEC, Scottish Heart Health Extended Cohort; 60YO, 60-year-old 
Swedish men and women; 3C Study: Three City Study; ULSAM-50 &-70: Uppsala Longitudinal Study of Adult Men investigations at ages 50 y and 
70 y, respectively. ‡PC, prospective cohort; PCC, prospective nested case-control; PNC, prospective nested case-cohort; RCC, retrospective case-
control. §AT, adipose tissue; CE, cholesterol ester; PP, plasma phospholipid; RBC, erythrocyte phospholipid; TP, total plasma. ||CVD, cardiovascular 
disease; CHD, coronary heart disease; MI, myocardial infarction. #All specified outcomes (total CVD, CVD mortality, total CHD, and ischemic 
stroke) were assessed. **In DCH, the association of adipose tissue arachidonic acid, but not linoleic acid, with total CHD was evaluated. ††Fatty acids 
were measured in cholesterol ester and adipose tissue at the first and third ULSAM investigation, respectively. 
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Table 2. Risk of incident CVD according to objective biomarker levels of linoleic acid (18:2n6) and arachidonic acid (20:4n6) in 30 
pooled prospective cohort studies. 
 
    Multivariable-adjusted hazard ratio (95% CI) 
per interquintile range† 
Outcome Biomarker Studies (n) Cases (n) Linoleic acid Arachidonic acid 
Total CVD Phospholipid 14 6 853 1.00 (0.92-1.09) 0.95 (0.87-1.03) 
 Total plasma 6 2 742 0.90 (0.78-1.03) 0.81 (0.70-0.94) 
 Cholesterol esters 4 1 300 0.74 (0.63-0.88) 1.03 (0.88-1.20) 
 Adipose tissue 2 1 412 0.87 (0.75-1.01) 0.98 (0.87-1.10) 
 Overall‡ 21 10 477 0.93 (0.88-0.99) 0.95 (0.90-1.01) 
      
CVD mortality Phospholipid 9 3 057 0.89 (0.79-1.00) 0.93 (0.83-1.05) 
 Total plasma 4 679 0.66 (0.50-0.86) 0.85 (0.66-1.09) 
 Cholesterol esters 3 473 0.56 (0.43-0.73) 0.99 (0.76-1.29) 
 Adipose tissue 2 418 0.60 (0.44-0.82) 1.02 (0.84-1.23) 
 Overall‡ 17 4 508 0.78 (0.70-0.85) 0.94 (0.86-1.02) 
      
Total CHD Phospholipid 14 6 075 1.01 (0.93-1.10) 0.96 (0.90-1.03) 
 Total plasma 7 2 430 0.86 (0.74-1.00) 0.86 (0.74-1.01) 
 Cholesterol esters 5 1 178 0.78 (0.65-0.94) 1.02 (0.85-1.23) 
 Adipose tissue 3§ 3 255 0.88 (0.74-1.03) 1.10 (0.98-1.23) 
 Overall‡  26§ 11 857 0.94 (0.88-1.00) 0.99 (0.94-1.04) 
      
Ischemic stroke Phospholipid 12 2 327 0.95 (0.82-1.10) 0.98 (0.85-1.13) 
 Total plasma 6 1 105 0.84 (0.66-1.06) 0.93 (0.73-1.18) 
 Cholesterol esters 4 598 0.67 (0.51-0.88) 1.13 (0.89-1.43) 
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 Adipose tissue 2 405 0.87 (0.65-1.15) 0.91 (0.74-1.11) 
 Overall‡ 21 3 705 0.88 (0.79-0.98) 0.99 (0.90-1.10) 
*AA, arachidonic acid; CHD, coronary heart disease; CI, confidence interval; CVD, cardiovascular disease; LA, linoleic acid.  
†Based on harmonized, de novo individual-level analyses in each cohort, pooled using inverse-variance weighted meta-analysis. Risk was assessed 
according to the interquintile range (i.e., range between the midpoint of the bottom quintile [10th percentile] and the top quintile [90th percentile]) 
of each fatty acid, corresponding to the difference between the midpoint of the first and fifth quintiless. Study-specific analyses were adjusted for 
age (years), sex (male/female), race (Caucasian/non-Caucasian, or study-specific), field or clinical center if applicable (study-specific categories), 
body-mass index (BMI, kg/m2), education (less than high school graduate, high school graduate, some college or vocational school, college 
graduate), smoking (current, former, or never; if former not assessed, then current or not current), physical activity (quintiles of metabolic 
equivalents (METs) per week; or if METs unavailable, quintiles of study-specific definitions of physical or leisure activity), alcohol intake (none, 
1-6 drinks/week, 1-2 drink/day, >2 drink/day [14 g alcohol=1 standard drink]), diabetes mellitus (yes/no; defined as treatment with oral 
hypoglycemic agents, insulin, or fasting plasma glucose >126 mg/dL), treated hypertension (yes/no; defined as hypertension drug use; or if 
unavailable, as diagnosed/history of hypertension according to study-specific definitions), treated hypercholesterolemia (yes or no; defined as 
lipid-lowering drug use; if unavailable, as diagnosed/history of hypercholesterolemia according to study-specific definitions), regular aspirin use 
(yes/no), biomarker concentrations of α-linolenic acid (ALA; 18:3n-3), eicosapentaenoic acid (EPA; 20:5n-3), sum of trans-18:1 fatty acids, and 
sum of trans-18:2 fatty acids (each expressed as % total fatty acids).  
‡For studies that assessed LA and AA levels in more than one biomarker compartment, the primary compartment for that study was pre-selected 
for pooled analyses based on the following order: 1) adipose tissue, 2) erythrocyte phospholipid, 3) plasma phospholipid 4) cholesterol ester, and 
5) total plasma. 
§Because the Diet, Cancer and Health study assessed associations of AA, but not LA, with total CHD (n cases=2138), a total of, 2 studies (n 
cases= 1117) evaluated adipose tissue LA and 25 studies (n cases=9719) assessed any biomarker level of LA in relation to total CHD. 
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Figure Legends  
 
Figure 1. Concentration of A) linoleic acid (LA; 18:2n6) and B) arachidonic acid (AA; 
20:4n6) across different biomarker compartments measured in the 31 contributing studies. 
Concentrations of arachidonic acid and linoleic acid concentrations are expressed as % of total 
fatty acids (FA), and indicated as median (circles) and interquintile range (lines; defined as the 
range between the midpoint of the bottom quintile [10th percentile] and the top quintile [90th 
percentile]), respectively. For MPCDRF and the MORGEN, values are only shown for 
controls.*Total number of individual FA measured in the biomarker compartment. †Not reported. 
 
Figure 2. Associations of linoleic acid (LA; 18:2n6) with total CVD (A) and CVD mortality 
(B) in pooled analysis of 30 prospective studies. Study-specific estimates for hazard ratio (HR) 
per interquintile range (i.e., range between the midpoint of the bottom quintile [10th percentile] 
and the top quintile [90th percentile]) of biomarker linoleic acid were pooled based on the 
following order: 1) adipose tissue, 2) erythrocyte phospholipid, 3) plasma phospholipid 4) 
cholesterol ester, and 5) total plasma. Study weights are indicated (grey squares) by individual 
biomarker compartment and overall. Study-specific analyses were conducted using models that 
included the following covariates: age (years), sex (male/female), race (Caucasian/non-
Caucasian, or study-specific), field center if applicable (categories), body-mass index (BMI, 
kg/m2), education (less than high school graduate, high school graduate, some college or 
vocational school, college graduate), smoking (current, former, never; if history not assessed, 
then current/not current), physical activity (quintiles of metabolic equivalents (METs)/ week), 
alcohol intake (none, 1-6 drinks/week, 1-2 drinks/day, >2 drinks/day), prevalent diabetes 
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mellitus (defined as treatment with oral antihyperglycemic agents, insulin, or fasting plasma 
glucose >126 mg/dL), treated hypertension (defined as hypertension drug use; or if unavailable, 
as diagnosed/history of hypertension), treated hypercholesterolemia (defined as LDL-lowering 
drug use; if unavailable, as diagnosed/history of hypercholesterolemia), regular aspirin use 
(defined as ≥2 times/week), levels of α-linolenic acid (ALA; 18:3n-3), eicosapentaenoic acid 
(EPA; 20:5n-3), sum of trans isomers of oleic acid (trans18:1), and sum of trans isomers of LA 
(trans-18:2) (each expressed as % total FAs). If data did not allow such categorization, study-
specific categories were used. See Table 1 footnote for abbreviations of cohorts. 
 
Figure 3. Associations of linoleic acid (LA; 18:2n6) with total CHD (A) and ischemic stroke 
(B) in pooled analysis of 30 prospective studies. Study-specific estimates for hazard ratio (HR) 
per interquintile range (i.e., range between the midpoint of the bottom quintile [10th percentile] 
and the top quintile [90th percentile]) of biomarker linoleic acid were pooled based on the 
following order: 1) adipose tissue, 2) erythrocyte phospholipid, 3) plasma phospholipid 4) 
cholesterol ester, and 5) total plasma. Study weights are indicated (grey squares) by individual 
biomarker compartment and overall. Study-specific analyses were conducted using models that 
included the following covariates: age (years), sex (male/female), race (Caucasian/non-
Caucasian, or study-specific), field center if applicable (categories), body-mass index (BMI, 
kg/m2), education (less than high school graduate, high school graduate, some college or 
vocational school, college graduate), smoking (current, former, never; if history not assessed, 
then current/not current), physical activity (quintiles of metabolic equivalents (METs)/ week), 
alcohol intake (none, 1-6 drinks/week, 1-2 drinks/day, >2 drinks/day), prevalent diabetes 
mellitus (defined as treatment with oral antihyperglycemic agents, insulin, or fasting plasma 
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glucose >126 mg/dL), treated hypertension (defined as hypertension drug use; or if unavailable, 
as diagnosed/history of hypertension), treated hypercholesterolemia (defined as LDL-lowering 
drug use; if unavailable, as diagnosed/history of hypercholesterolemia), regular aspirin use 
(defined as ≥2 times/week), levels of α-linolenic acid (ALA; 18:3n-3), eicosapentaenoic acid 
(EPA; 20:5n-3), sum of trans isomers of oleic acid (trans18:1), and sum of trans isomers of LA 
(trans-18:2) (each expressed as % total FAs). If data did not allow such categorization, study-
specific categories were used. See Table 1 footnote for abbreviations of cohorts. 
 
Figure 4. Associations of arachidonic acid (AA; 20:4n6) with total CVD (A) and CVD 
mortality (B) in pooled analysis of 30 prospective studies.  
Study-specific estimates for hazard ratio (HR) per interquintile range (i.e., range between the 
midpoint of the bottom quintile [10th percentile] and the top quintile [90th percentile]) of 
biomarker linoleic acid were pooled based on the following order: 1) adipose tissue, 2) 
erythrocyte phospholipid, 3) plasma phospholipid 4) cholesterol ester, and 5) total plasma. Study 
weights are indicated (grey squares) by individual biomarker compartment and overall. Study-
specific analyses were conducted using models that included the following covariates: age 
(years), sex (male/female), race (Caucasian/non-Caucasian, or study-specific), field center if 
applicable (categories), body-mass index (BMI, kg/m2), education (less than high school 
graduate, high school graduate, some college or vocational school, college graduate), smoking 
(current, former, never; if history not assessed, then current/not current), physical activity 
(quintiles of metabolic equivalents (METs)/ week), alcohol intake (none, 1-6 drinks/week, 1-2 
drinks/day, >2 drinks/day), prevalent diabetes mellitus (defined as treatment with oral 
antihyperglycemic agents, insulin, or fasting plasma glucose >126 mg/dL), treated hypertension 
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(defined as hypertension drug use; or if unavailable, as diagnosed/history of hypertension), 
treated hypercholesterolemia (defined as LDL-lowering drug use; if unavailable, as 
diagnosed/history of hypercholesterolemia), regular aspirin use (defined as ≥2 times/week), 
levels of α-linolenic acid (ALA; 18:3n-3), eicosapentaenoic acid (EPA; 20:5n-3), sum of trans 
isomers of oleic acid (trans18:1), and sum of trans isomers of LA (trans-18:2) (each expressed 
as % total FAs). If data did not allow such categorization, study-specific categories were used. 
See Table 1 footnote for abbreviations of cohorts. 
 
Figure 5. Associations of arachidonic acid (AA; 20:4n6) with total CHD (A) and ischemic 
stroke (B) in pooled analysis of 30 prospective studies.  
Study-specific estimates for hazard ratio (HR) per interquintile range (i.e., range between the 
midpoint of the bottom quintile [10th percentile] and the top quintile [90th percentile]) of 
biomarker linoleic acid were pooled based on the following order: 1) adipose tissue, 2) 
erythrocyte phospholipid, 3) plasma phospholipid 4) cholesterol ester, and 5) total plasma. Study 
weights are indicated (grey squares) by individual biomarker compartment and overall. Study-
specific analyses were conducted using models that included the following covariates: age 
(linear), sex (male/female), race (binary: Caucasian/non-Caucasian, or study-specific), field or 
clinical center if applicable (study-specific categories), body-mass index (BMI, linear), education 
(less than high school graduate, high school graduate, some college or vocational school, college 
graduate), smoking (current, former, or never; if former not assessed, then current or not 
current), physical activity (quintiles of metabolic equivalents (METs) per week; or if METs 
unavailable, quintiles of study-specific definitions of physical or leisure activity), alcohol intake 
(none, 1-6 drinks/week, 1-2 drink/day, >2 drink/day [14 g alcohol=1 standard drink]), diabetes 
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mellitus (yes or no; defined as treatment with oral hypoglycemic agents, insulin, or fasting 
plasma glucose >126 mg/dL), treated hypertension (yes or no; defined as hypertension drug use; 
or if unavailable, as diagnosed/history of hypertension according to study-specific definitions), 
treated hypercholesterolemia (yes or no; defined as lipid-lowering drug use; if unavailable, as 
diagnosed/history of hypercholesterolemia according to study-specific definitions), regular 
aspirin use (yes or no), biomarker concentrations of α-linolenic acid (ALA; 18:3n-3), 
eicosapentaenoic acid (EPA; 20:5n-3), sum of trans-18:1 fatty acids, and sum of trans-18:2 fatty 
acids (all linear; expressed as % total fatty acids). If data did not allow such categorization, 
study-specific categories were used. See Table 1 footnote for abbreviations of cohorts. 
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